Neuroscience Today—June 24, 2026

This week’s Neuroscience update highlights regulatory approvals, filing milestones, breakthrough designations, clinical advances, AI-enabled discovery partnerships, and continued innovation across neurology, migraine, and rare disease programs.

In Today’s Newsletter

Dive deeper

💊 Ecopipam NDA for pediatric Tourette syndrome [1] [US • 18 Jun 2026]

https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Submits-NDA-for-Ecopipam-a-First-in-Class-Investigational-Therapy-for-Pediatric-Tourette-Syndrome/default.aspx
Context: Phase 3 data showed significantly delayed time to relapse versus placebo in pediatric responders, with p=0.008.
Key point: Teva submitted an NDA to FDA for ecopipam, a selective dopamine D1 receptor antagonist for pediatric Tourette syndrome.
Implication: May influence prescriber choice and payer reviews pending full data.

🧠 J&J MEMBRANE trial in chronic subdural hematoma [2] [US–China • 19 Jun 2026]

https://www.jnj.com/media-center/press-releases/johnson-johnson-highlights-positive-results-from-membrane-trial-published-in-jama-neurology
Context: MEMBRANE randomized 376 patients across 30 sites in the US and China, with a 6-month composite primary endpoint.
Key point: Johnson & Johnson said TRUFILL n-BCA MMA embolization plus standard care reduced cSDH recurrence and re-intervention versus standard care alone.
Implication: May influence prescriber choice and payer reviews pending full data.

💉 Viatris fast-acting meloxicam NDA accepted [3] [US • 18 May 2026]

https://newsroom.viatris.com/2026-05-18-U-S-FDA-Accepts-Viatris-New-Drug-Application-for-Fast-Acting-Meloxicam-for-the-Treatment-of-Moderate-to-Severe-Acute-Pain
Context: The PDUFA goal date is 27 Dec 2026, supported by two Phase 3 trials in herniorrhaphy and bunionectomy pain.
Key point: FDA accepted Viatris’ NDA for MR-107A-02, fast-acting meloxicam, for moderate-to-severe acute pain.
Implication: May influence prescriber choice and payer reviews pending full data.

🧬 Vedana migraine antibody pipeline launches [4] [17 Jun 2026]

https://www.fiercebiotech.com/biotech/vedana-therapeutics-surfaces-46m-develop-next-gen-migraine-therapy
Context: The lead program targets PACAP, and a second bispecific antibody targets PACAP and CGRP; both are preclinical.
Key point: Vedana Therapeutics launched with $46 million in Series A financing for subcutaneous migraine-prevention antibodies.
Implication: Signals pipeline investment and modality expansion.

🔬 Insilico ISM8969 enters Phase 1 dosing [5] [Australia • 17 Jun 2026]

https://www.manilatimes.net/2026/06/17/tmt-newswire/pr-newswire/insilico-completes-first-in-human-dosing-in-phase-i-clinical-study-of-ai-driven-nlrp3-inhibitor-ism8969-achieving-first-clinical-milestone-in-collaboration-with-hygtia-therapeutics/2367576
Context: The Phase 1 SAD/MAD trial in Australia will assess safety, tolerability, PK, and PD in healthy and obese participants.
Key point: Insilico Medicine completed first-in-human dosing for ISM8969, an oral brain-penetrant NLRP3 inhibitor.
Implication: May influence prescriber choice and payer reviews pending full data.

🤝 Insilico and SK Biopharm sign CNS AI discovery deal [6] [APAC • 22 Jun 2026]

https://www.fiercebiotech.com/biotech/insilico-lands-heavily-backloaded-25b-ai-drug-discovery-deal-sk-biopharm
Context: Terms include $18 million in upfront and near-term milestones, with SK leading late-stage development and commercialization.
Key point: Insilico Medicine and SK Biopharmaceuticals signed an AI-enabled CNS drug discovery alliance worth up to $2.5 billion.
Implication: Signals pipeline investment and modality expansion.

🧪 Sanofi Cenrifki approved for nrSPMS in EU [7] [EU • 23 Jun 2026]

https://www.sanofi.com/en/media-room/press-releases/2026/2026-06-23-05-00-00-3315699
Context: Approval was based on HERCULES Phase 3 data in nrSPMS, with supporting GEMINI 1 and 2 data in RMS.
Key point: The European Commission approved Cenrifki (tolebrutinib) for SPMS without relapses in the last two years.
Implication: May influence prescriber choice and payer reviews pending full data.

🧫 Pheno PTD802 receives FDA IND clearance [8] [US • 22 Jun 2026]

https://phenotherapeutics.com/pheno-therapeutics-granted-fda-ind-clearance-for-lead-multiple-sclerosis-therapeutic-candidate-ptd802/
Context: PTD802 is designed to promote remyelination; the first-in-human study will evaluate safety and tolerability in healthy volunteers.
Key point: FDA cleared Pheno Therapeutics’ IND for PTD802, a selective GPR17 antagonist for neurological diseases including MS.
Implication: Signals pipeline investment and modality expansion.

⚡ Capri Medical LUNA cleared for first-in-human trials [9] [EU • 22 Jun 2026]

https://irishtechnews.ie/irish-medtech-company-leads-eu-breakthrough/
Context: LUNA-INJECT is designed for outpatient implantation under local anaesthesia, replacing a longer surgical workflow.
Key point: Capri Medical and the EU-funded TARA consortium completed product development for the LUNA migraine neurostimulation platform.
Implication: May expand screening, initiation, and follow-up at scale.

🧠 Praxis elsunersen receives FDA Breakthrough Therapy Designation [10] [US • 22 Jun 2026]

https://www.manilatimes.net/2026/06/22/tmt-newswire/globenewswire/praxis-precision-medicines-receives-fda-breakthrough-therapy-designation-for-elsunersen-for-the-treatment-of-seizures-associated-with-scn2a-developmental-and-epileptic-encephalopathy-caused-by-gain-of-function-variants/2370058
Context: EMBRAVE Part A showed a 77% sham-adjusted monthly seizure reduction, with EMBRAVE3 enrolling under a single-arm pathway.
Key point: FDA granted Breakthrough Therapy Designation to elsunersen for seizures tied to SCN2A-DEE gain-of-function variants.
Implication: May influence prescriber choice and payer reviews pending full data.

Why it matters

CNS regulatory activity is accelerating across Tourette syndrome, SPMS, acute pain, MS remyelination, and rare epilepsy.
AI-enabled drug discovery remains active in CNS, with Insilico advancing both internal clinical assets and partnered discovery deals.
Migraine innovation is moving across antibodies, PACAP biology, and implantable neurostimulation platforms.
Rare and pediatric neurology programs are using expedited pathways, including Orphan, Fast Track, PRIME, and Breakthrough Therapy designations.
Device and drug programs are converging around outpatient access, disability progression, and targeted mechanisms.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

📚 View the full Neuroscience archive on our research hub page

🎯 Catch up on the Top Neuroscience news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

FAQ

What is Teva’s ecopipam being reviewed for?

Ecopipam is being submitted by Teva for pediatric Tourette syndrome. The NDA is supported by Phase 3 data showing delayed relapse versus placebo in pediatric responders [1].

Why is Sanofi’s Cenrifki approval notable?

Cenrifki (tolebrutinib) was approved in the EU for SPMS without relapses in the last two years. Sanofi says it targets disability progression, based on HERCULES Phase 3 data [7].

What does Praxis’ Breakthrough Therapy Designation cover?

The FDA designation covers elsunersen for seizures associated with SCN2A-DEE caused by gain-of-function variants. It was supported by EMBRAVE Part A data [10].

What is Vedana Therapeutics developing for migraine?

Vedana is developing subcutaneous antibodies for migraine prevention. Its lead program targets PACAP, and a second bispecific targets PACAP and CGRP [4].

What is Insilico’s ISM8969?

ISM8969 is an oral, brain-penetrant NLRP3 inhibitor being studied in Phase 1. The trial is designed to evaluate safety, tolerability, PK, and PD [5].

What is Capri Medical’s LUNA platform?

LUNA is a neurostimulation platform for chronic migraine. Capri Medical’s LUNA-INJECT delivery system is intended to enable outpatient implantation under local anaesthesia [9].

Entities / Keywords

Teva Pharmaceutical Industries, ecopipam, dopamine D1 receptor antagonist, pediatric Tourette syndrome, NDA, FDA
Johnson & Johnson MedTech, MEMBRANE, TRUFILL n-BCA, middle meningeal artery embolization, MMAe, chronic subdural hematoma, cSDH
Viatris, MR-107A-02, fast-acting meloxicam, acute pain, non-opioid analgesic, PDUFA
Vedana Therapeutics, PACAP, CGRP, migraine prevention, anti-PACAP antibody, bispecific antibody
Insilico Medicine, Hygtia Therapeutics, ISM8969, NLRP3 inhibitor, neuroinflammation, Parkinson’s disease, Phase 1
SK Biopharmaceuticals, Pharma.AI, CNS AI drug discovery, neuroimmune disorders, Xcopri, cenobamate
Sanofi, Cenrifki, tolebrutinib, HERCULES, GEMINI 1, GEMINI 2, nrSPMS, RMS
Pheno Therapeutics, PTD802, GPR17 antagonist, remyelination, multiple sclerosis, IND
Capri Medical, TARA consortium, LUNA Platform, LUNA-INJECT, neurostimulation, chronic migraine
Praxis Precision Medicines, elsunersen, PRAX-222, SCN2A-DEE, EMBRAVE, ASO, Breakthrough Therapy Designation